Assembly Biosciences ASMB
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Assembly Biosciences (ASMB)
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Key Insights
Critical company metrics and information
Latest Closing Price
$11.12Market Cap
$70.68 MillionPrice-Earnings Ratio
-1.61Total Outstanding Shares
6.36 Million SharesTotal Employees
65Dividend
No dividendIPO Date
December 17, 2010SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
Two tower place, South san francisco, CA, 94080Homepage
https://www.assemblybio.com
Historical Stock Splits
If you bought 12 shares of ASMB before February 12, 2024, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| February 12, 2024 | 1-for-12 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-42.79 Million |
| Net Cash Flow | $1.80 Million |
| Net Cash Flow From Operating Activities | $22.94 Million |
| Net Cash Flow From Investing Activities | $-42.79 Million |
| Net Cash Flow From Operating Activities, Continuing | $22.94 Million |
| Net Cash Flow, Continuing | $1.80 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit | $439,000 |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Operating Income/Loss | $-46.44 Million |
| Revenues | $28.33 Million |
| Research and Development | $52.66 Million |
| Nonoperating Income/Loss | $6.07 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-20.65 Million |
| Comprehensive Income/Loss Attributable To Parent | $-40.69 Million |
| Comprehensive Income/Loss | $-40.69 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Fixed Assets | $316,000 |
| Noncurrent Assets | $2.05 Million |
| Current Liabilities | $41.63 Million |
| Other Non-current Assets | $1.73 Million |
| Wages | $4.12 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ASMB from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.